Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Fulcrum therapeutics, inc. save search
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
Published: 2023-08-22 (Crawled : 11:00) - globenewswire.com
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 37.86%
H: 20.64%
C: 2.84%
ftx-6058 fda disease cell
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
Published: 2023-02-24 (Crawled : 13:20) - globenewswire.com
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: -54.85%
H: 0.0%
C: 0.0%
ftx-6058 disease therapeutics clinical hold
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
Published: 2022-06-10 (Crawled : 12:20) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: -17.12%
H: 0.0%
C: 0.0%
ftx-6058 ongoing disease trial therapeutics phase 2b
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
Published: 2022-05-12 (Crawled : 00:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
ftx-6058 disease trial therapeutics living phase 2b
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
Published: 2021-12-06 (Crawled : 15:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
trial therapeutics disease preclinical phase 1 pre-clinical
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
Published: 2021-08-10 (Crawled : 13:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 58.58%
H: 67.22%
C: 42.09%
disease phase 1 positive results trial phase 2 phase 3
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Published: 2021-06-24 (Crawled : 12:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 1.09%
H: 16.97%
C: -5.08%
disease results trial
Fulcrum Therapeutics Recognizes Rare Disease Day 2021Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world
Published: 2021-02-26 (Crawled : 13:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 1.41%
H: 2.36%
C: -2.63%
disease rare
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
Published: 2021-02-26 (Crawled : 12:03) - globenewswire.com
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 1.41%
H: 2.36%
C: -2.63%
disease therapeutics rare
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
Published: 2020-12-09 (Crawled : 12:04) - globenewswire.com
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: 1.37%
H: 5.69%
C: -0.82%
disease
Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2020-12-05 (Crawled : 15:00) - globenewswire.com
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
| Email alert
Add to watchlist
disease
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.